Publications

Han Y, Shaw VR, Byun J, Thrift AP, Zhu C, Li D, Hatia RI, Kelley RK, Cleary SP, Lok AS, Bracci PM, Permuth JB, Bucur R, Knox J, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Kono Y, Shah DP, Nguyen MH, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Chun YS, Gu J, Huff C, Rashid A, Hwang LY, Klein AP, Khaderi SA, Kaseb AO, McGlynn KA, Roberts LR, Hassan MM, Amos CI. Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits. International journal of cancer. 2025. PMID: 41013983

Vesuna F, Winnard PT, van Voss MH, Bol GM, Ter Hoeve ND, van Diest PJ, Raman V. Inhibition of DDX3 modulates immune signaling in aggressive breast cancers. Cancer letters. 2025. PMID: 41016677

Ho LS, Braat MNGJA, Bol G, Smits MLJ, Lam MGEH, Braat AJAT. Can non-tumorous liver tissue serve as a reliable reference measure for [18F]FDG-PET-CT after unilobar 90Y glass radioembolization in patients with colorectal liver metastases? EJNMMI research. 2025. PMID: 41003938

Liu Q, Chen PA, Urs E, Zhang S, Arce MM, Wang CH, Li Z, Seo J, Kale N, LaFlam TN, Peng F, Shifrut E, Allen GM, Eyquem J, Fuh K, Dodgson SE, Cyster JG, Marson A, Carnevale J. In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors. bioRxiv : the preprint server for biology. 2025. PMID: 41040261

Smabers LP, Wensink GE, Verissimo CS, Doorn M, Yang T, Voskuilen T, Huismans MA, Valkenburg-van Iersel L, Cirkel GA, Gootjes EC, Verheul HMW, Jeurissen FJ, Bol GM, Nienhuis HH, Braat MNGJA, Cuppen E, Vries RGJ, van der Baan FH, Elias SG, Kranenburg O, Koopman M, Boj SF, Roodhart JML. Patient-derived organoids predict treatment response in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40982295

Chari A, van de Donk NWCJ, Dholaria B, Weisel KC, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosiñol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi KK, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit D, Wäsch R. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025. PMID: 40983036

Mushi BP, Haddadi S, Mrema A, Ndumbalo J, Mvungi N, Selekwa M, Mwaiselage J, Akoko L, Ringo Y, Luhar R, DeBoer R, Loon KV, Mmbaga E, Buckle GC. Colorectal cancer care in Tanzania: an evaluation of clinical characteristics, treatment patterns and quality metrics at a national cancer referral hospital. Ecancermedicalscience. 2025. PMID: 41561545

Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40689871

Chari A, Shenoy S, Kruyswijk S, Hilder B, O'Rourke L, van de Donk NWCJ. Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary. Future oncology (London, England). 2025. PMID: 40951933

Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. European urology. 2025. PMID: 40954009

Xu MJ, Decker H, Abreu A, Patterson RH, Nteyumwete H, Beaudoin PL, Hamilton DW, Nkya A, Massawe W, Correia N, Paulo FY, Van Loon K, Emmett SD, Reaves C, Okerosi S. Time to Measure: A Proposed Theoretical Model for Head and Neck Cancer Intervals of Care. World journal of otorhinolaryngology - head and neck surgery. 2025. PMID: 42205423

Courau T, Desai A, Wagner A, Combes AJ, Krummel MF. The coming era of nudge drugs for cancer. Cancer cell. 2025. PMID: 40939589

Kamgar M, Ko AH. Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40929645

Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY, Solit DB, Rosenberg JE, Al-Ahmadie H, Ding CCK, Chan E, Steri V, Porten SP, Koshkin VS, Friedlander TW, Feng FY, Lee JK, Wiita AP, Chu CE, Chou J. Modulating the PPAR? pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nature communications. 2025. PMID: 40931013

Reese SW, Barbakoff D, Ucpinar BA, Knezevic A, Fitzgerald K, Eismann L, Tehrani YM, Arroyave JS, Khaleel S, Khandwala YS, Dawidek M, Motzer RJ, Voss MH, Russo P, Akin O, Kotecha RR, Hakimi AA. Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma. Urologic oncology. 2025. PMID: 40914665

Salami A, Adiele U, Coate G, Diolaiti M, Chen H, Lu J, Ashworth A, Patil M, Fleishman JS, Ramaraju A, Patel A, Patel H, Patel K, Murakami M, Ambudkar SV, Talele TT. Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors. Bioorganic chemistry. 2025. PMID: 40945025

Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, Yoshino T, Cremolini C. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40906970

Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson SA, Butte AJ. An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL. Blood advances. 2025. PMID: 40902085

Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40902132

Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies. JCO precision oncology. 2025. PMID: 40893049